BioLineRx Capital Expenditures (CapEx) Growth & History (BLRX)
BioLineRx's capital expenditures (capex) was $25,000 for fiscal 2025.
View full BioLineRx company overviewBioLineRx annual capital expenditures (capex) history
| Fiscal year | Period ended | Capital expenditures (CapEx) | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $25,000 | −$28,000 | −52.83% |
| 2024 | 2024-12-31 | $53,000 | −$63,000 | −54.31% |
| 2023 | 2023-12-31 | $116,000 | −$15,000 | −11.45% |
| 2022 | 2022-12-31 | $131,000 | $34,000 | +35.05% |
| 2021 | 2021-12-31 | $97,000 | $97,000 | — |
| 2020 | 2020-12-31 | $0 | −$67,000 | — |
| 2019 | 2019-12-31 | $67,000 | −$106,000 | −61.27% |
| 2018 | 2018-12-31 | $173,000 | −$165,000 | −48.82% |
| 2017 | 2017-12-31 | $338,000 | $286,000 | +550.00% |
| 2016 | 2016-12-31 | $52,000 | −$2.6M | −98.06% |
| 2015 | 2015-12-31 | $2.7M | — | — |
BioLineRx quarterly capital expenditures (capex)
| Fiscal quarter | Period ended | Capital expenditures (CapEx) | Change | YoY change |
|---|---|---|---|---|
| Q1 2026 | 2026-03-31 | $6,000 | — | — |
BioLineRx capital expenditures (capex) trends
Over the last five fiscal years, BioLineRx's capital expenditures (capex) increased from $0 to $25,000, a change of $25,000. The latest reported quarter, Q1 2026, shows $6,000.
What capital expenditures (CapEx) mean
Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.
SEC-reported capital expenditures
TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review BioLineRx source filings ↗